94 related articles for article (PubMed ID: 16220971)
1. Selective inhibition of MCF-7(piGST) breast tumors using glutathione transferase-derived 2-methylene-cycloalkenones.
Joseph E; Ganem B; Eiseman JL; Creighton DJ
J Med Chem; 2005 Oct; 48(21):6549-52. PubMed ID: 16220971
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of the glutathione transferase-catalyzed conversion of antitumor 2-crotonyloxymethyl-2-cycloalkenones to GSH adducts.
Hamilton DS; Zhang X; Ding Z; Hubatsch I; Mannervik B; Houk KN; Ganem B; Creighton DJ
J Am Chem Soc; 2003 Dec; 125(49):15049-58. PubMed ID: 14653739
[TBL] [Abstract][Full Text] [Related]
3. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa.
Srivastava SK; Singhal SS; Hu X; Awasthi YC; Zimniak P; Singh SV
Arch Biochem Biophys; 1999 Jun; 366(1):89-94. PubMed ID: 10334868
[TBL] [Abstract][Full Text] [Related]
4. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
Morgan AS; Sanderson PE; Borch RF; Tew KD; Niitsu Y; Takayama T; Von Hoff DD; Izbicka E; Mangold G; Paul C; Broberg U; Mannervik B; Henner WD; Kauvar LM
Cancer Res; 1998 Jun; 58(12):2568-75. PubMed ID: 9635580
[TBL] [Abstract][Full Text] [Related]
5. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
Wang W; Liu G; Zheng J
Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.
Nakajima T; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Abe T; Kato J; Sakon K; Naniwa Y; Tanabe H; Niitsu Y
J Pharmacol Exp Ther; 2003 Sep; 306(3):861-9. PubMed ID: 12805482
[TBL] [Abstract][Full Text] [Related]
7. Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil.
Pandya U; Srivastava SK; Singhal SS; Pal A; Awasthi S; Zimniak P; Awasthi YC; Singh SV
Biochem Biophys Res Commun; 2000 Nov; 278(1):258-62. PubMed ID: 11071881
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of the antitumor activities of 2-crotonyloxymethyl-2-cycloalkenones.
Joseph E; Eiseman JL; Hamilton DS; Wang H; Tak H; Ding Z; Ganem B; Creighton DJ
J Med Chem; 2003 Jan; 46(1):194-6. PubMed ID: 12502374
[TBL] [Abstract][Full Text] [Related]
9. Cellular response to a glutathione S-transferase P1-1 activated prodrug.
Rosario LA; O'Brien ML; Henderson CJ; Wolf CR; Tew KD
Mol Pharmacol; 2000 Jul; 58(1):167-74. PubMed ID: 10860939
[TBL] [Abstract][Full Text] [Related]
10. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
11. Resistance to cisplatin and adriamycin is associated with the inhibition of glutathione efflux in MCF-7-derived cells.
Osbild S; Brault L; Battaglia E; Bagrel D
Anticancer Res; 2006; 26(5A):3595-600. PubMed ID: 17094488
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis.
Yu ST; Chen TM; Chern JW; Tseng SY; Chen YH
Anticancer Drugs; 2009 Jun; 20(5):382-8. PubMed ID: 19318911
[TBL] [Abstract][Full Text] [Related]
13. Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy.
Tercel M; Yang S; Atwell GJ; Smith E; Gu Y; Anderson RF; Denny WA; Wilson WR; Pruijn FB
Bioorg Med Chem; 2010 Jul; 18(14):4997-5006. PubMed ID: 20580559
[TBL] [Abstract][Full Text] [Related]
14. Decreased cytotoxicity and increased antimitotic activity of proline analogue of chlorambucil as a prodrug in breast cancer MCF-7 cells.
Bielawska A; Chrzanowski K; Bielawski K; Pałka J
Acta Pol Pharm; 2000 Nov; 57 Suppl():103-5. PubMed ID: 11293233
[No Abstract] [Full Text] [Related]
15. Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug.
Xu H; Wang Z; Donaldson JC; Yao H; Zhou S; Kelson AB; Ma W; Weber KT; Laborde E; Cheng M; Sambucetti L; Keck JG
Anticancer Res; 2009 Oct; 29(10):3845-55. PubMed ID: 19846918
[TBL] [Abstract][Full Text] [Related]
16. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
Newman SP; Foster PA; Stengel C; Day JM; Ho YT; Judde JG; Lassalle M; Prevost G; Leese MP; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Jan; 14(2):597-606. PubMed ID: 18223236
[TBL] [Abstract][Full Text] [Related]
17. Peptide-bond modified glutathione conjugate analogs modulate GSTpi function in GSH-conjugation, drug sensitivity and JNK signaling.
Burg D; Riepsaame J; Pont C; Mulder G; van de Water B
Biochem Pharmacol; 2006 Jan; 71(3):268-77. PubMed ID: 16337611
[TBL] [Abstract][Full Text] [Related]
18. Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I.
Kamiya D; Uchihata Y; Ichikawa E; Kato K; Umezawa K
Bioorg Med Chem Lett; 2005 Feb; 15(4):1111-4. PubMed ID: 15686923
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
[TBL] [Abstract][Full Text] [Related]
20. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter.
Gao P; Zhou GY; Guo LL; Zhang QH; Zhen JH; Fang AJ; Lin XY
Cancer Lett; 2007 Oct; 256(1):81-9. PubMed ID: 17637500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
